Navigation Links
Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events
Date:5/6/2008

Pharmacogenetic Findings May Lead to Individualized Treatment for

Schizophrenia

WASHINGTON, MAY 6 /PRNewswire-FirstCall/ -- Data presented today on Vanda Pharmaceuticals Inc.'s (Nasdaq: VNDA) investigational drug candidate, iloperidone, included its 4-week, short-term Phase III trial, as well as a pooled analysis of three long-term, 52-week trials, studying the efficacy and safety of iloperidone. Iloperidone is a 5HT2/D2 antagonist ("atypical") antipsychotic currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia. Additional data were presented identifying genetic markers that may help predict response to iloperidone, which Vanda believes could lead to unique, individualized treatment for schizophrenia. These data were presented today at the 161st American Psychiatric Association (APA) Annual Meeting in Washington, D.C.

"The data from the clinical trials studying the efficacy and safety of iloperidone suggest that iloperidone could be a useful long-term treatment option for people with schizophrenia," said Peter Weiden, M.D., Director of the Psychosis Program of the Department of Psychiatry at the University of Illinois at Chicago and one of the leading experts on adverse events of antipsychotic medications.

The data presented are part of the New Drug Application (NDA) submitted and currently under review by the FDA and demonstrate that iloperidone is effective in the short-term treatment of schizophrenia and that iloperidone is non-inferior to haloperidol in long-term maintenance measured as time to relapse over 52 weeks. In these trials, iloperidone showed short- and long- term safety with respect to movement disorders and metabolic e
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Treprostinil Data to be Presented at Annual Meeting of the American Thoracic Society
2. New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
3. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
4. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
5. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
7. Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
8. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
9. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
10. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
11. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - SQI ... that develops and commercializes proprietary technologies and products ... has entered into a Master Service Agreement to ... DNA-based pathogen detection assays. During the initial phase ... deliver an automated working prototype of one of ...
(Date:8/21/2014)... 21, 2014  Aptuit LLC announces that Aptuit ... , has enhanced its capabilities in the ... and large molecules, including biologic drugs, metabolites, and ... Q-TOF mass spectrometer. In making the ... said, "The expanded large molecule capability enhances our ...
(Date:8/21/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... health, has appointed Holly B. Bauzon as ... Ms. Bauzon has a proven track record in both ... services companies. She has more than 20 years of ... held the position of Director, Lab Services Sales and ...
Breaking Medicine Technology:SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2
... announced that its Board of Directors has appointed Dirk Allison ...  Mr. Allison has been the interim CEO of the Company ... joining CCS Medical as its President and Chief Executive Officer," ... and I look forward to continuing our growth in diabetes, ...
... March 21, 2011 Echo Therapeutics, Inc. (OTC Bulletin ... needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal ... System for transdermal drug delivery, today announced results for ... on Form 10-K is available through Echo,s website at ...
Cached Medicine Technology:Echo Therapeutics Announces 2010 Financial Results 2Echo Therapeutics Announces 2010 Financial Results 3Echo Therapeutics Announces 2010 Financial Results 4
(Date:8/22/2014)... 2014 Recently, iFitDress.com, a well-known wedding ... of discounted wedding gowns . In addition to ... these new products are provided with low shipping fees. ... to unveil the new wedding gowns. In our online ... for ladies to choose from. What’s more, all of ...
(Date:8/22/2014)... New Orleans, LA The LSU Health New ... Advanced Education Nursing Traineeship grant to increase access ... disadvantaged, underserved and under-represented groups, as well as ... the US Department of Health and Human Services ... will serve as the grant,s project director., The ...
(Date:8/22/2014)... 22, 2014 Natural Clear Vision , ... restore his own vision from legally blind to perfect 20/20 ... investigative review. , “There is a huge portion of ... everyday function, and most people just think that’s the way ... surgery that can be pretty risky at times,” reports Michaels. ...
(Date:8/22/2014)... time an oncogenic somatic mutation at amino acid 918 ... identified in small cell lung cancer (SCLC) tumors and ... produced increased intracellular signaling and cell growth. , SCLC ... 15% of all lung cancers and is strongly associated ... has been extensively examined for genomic alterations and targeted ...
(Date:8/22/2014)... Restore My Vision Today , ... Pearson to help people discover how they can get ... by instead improving their eyesight naturally has caught the ... , “There’s a reason why the glasses and contacts ... because people just assume that it’s their only option ...
Breaking Medicine News(10 mins):Health News:Discounted Wedding Gowns For Sale At Leading Online Shop iFitDress.com 2Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2
... disease could be more common than thought, experts say, , ... from rabies of a 17-year-old Texas girl -- diagnosed months ... their heads and wondering if such cases might be less ... possibility that abortive rabies can occur in humans and might ...
... ... enterprise platform for its revolutionary Evercore® – Enterprise Clinical Suite software system, now available ... ... Healthcare Technology , a leading medical informatics company, has launched a new enterprise platform ...
... ... ... ... ...
... , ... ... ... ...
... screening tool for early detection of prostate cancer (PCa) in ... PCa. The risk of suicide is increased among cancer patients ... among men diagnosed with PCa subsequent to PSA testing, a ... published in the March issue of European Urology , ...
... Two Spanish psychologists and a German neurologist have recently shown ... new noun is different from the part used when a ... taken using functional magnetic resonance, according to an article they ... "Learning nouns activates the left fusiform gyrus, while learning ...
Cached Medicine News:Health News:Texas Girl Recovers From Rabies Without Intensive Care 2Health News:TeraMedica Launches Evercore – Clinical Enterprise Suite 5.0 Now on Linux 2Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 2Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 3Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 4Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 5Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 6Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 7Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 8Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 9Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 10Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 11Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 12Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 13Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 14Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 15Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 16Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 17Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 18Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 19Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 20Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 21Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 22Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 23Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 24Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 25Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 26Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 27Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 28Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 29Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 30Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 31Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 32Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 33Health News:MedTrust Online Brings MICROMEDEX(R) DRUGDEX(R) From Thomson Reuters to Over 7,000 Online Oncologists 2
Hydrophobic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
... Hydroview™ hydrophilic acrylic IOL is the ... truly designed with the patient and surgeon ... a hydrogel optic polymerically crosslinked with PMMA ... use, and excellent visual performance and biocompatibility. ...
BIGBAG Hydrophilic Acrylic Lens for high myopia....
... Collamer™ lens, model CQ2003V, combines the best ... This lens contains a Collamer optic with ... angulation. These loops offer flexibility comparable to ... strength, and superior "shape memory". The light ...
Medicine Products: